Mommy, My Gas Mask Doesn't Fit!

Total Page:16

File Type:pdf, Size:1020Kb

Mommy, My Gas Mask Doesn't Fit! Mommy, My gas mask doesn’t fit! Pediatric Issues In Unconventional and Asymmetric Warfare James M. Howson, CEM, CHEC, NRP UMBC PACE Medic Recertification February, 2021 Disclaimers: This presentation was prepared by James Howson in his personal capacity. The opinions expressed in this presentation are the author's own and do not reflect the views of the National Institutes of Health, the Department of Health and Human Services, or the United States Government. No classified sources were used in putting together this presentation. All information presented in this talk was gleaned from “Open Source” materials. 1 Disclaimers Continued This presentation contains some images from actual terrorist and criminal events that my be disturbing to some viewers. “In the event of a terrorist attack, children would be one of the most vulnerable populations” US Department of Health and Human Services 2 “The use of chemical or biological weapons against a civilian population would disproportionately affect children” American Academy Of Pediatrics Unconventional Warfare Also called Asymmetric Warfare Unconventional strategies and tactics adopted by a force when the military capabilities of belligerent powers are not simply unequal but are so significantly different that they cannot make the same sorts of attacks on each other. Challenging the United States in conventional combat is an problematic, but use of unconventional weapons and tactics, such as those associated with guerrilla warfare and terrorist attacks can provide significant advantages. 3 Unconventional Warfare Continued Children are being specifically targeted. Kankara town, Nigeria (2020-12) Kidnaping of 333 boys from a school Similar to the kidnapping of 276 girls in Chibok, Nigeria by Boko Haram in 2014 In the 2014 attack girls were targeted and the boys were simply killed (57 boys) Peshawar, Pakistan (2014) Chemical Attack on School - 132 dead 57 boys were killed in the incident Beslan, Russia (2004) Attack on a school - 777 children held hostage, 331 killed Starogladovskaya, Chechnya (2005) Nerve agent attack on a middle school - over 100 dead Utoye Island, Norway (2011) Shooting attack on a youth camp, 69 dead, 33 were under the age of 18 Unconventional Warfare Continued Terrorist attacks against children have dramatically increased over the past 10 years. They have symbolic value There is significant media coverage Children and schools are considered “Soft Targets”, it is easy to inflict horrific damage on what are lightly defended targets. 4 Pediatric Issues In Asymmetric Warfare Areas of Concern Physiologic and Developmental Concerns Personal Protective Equipment Effective Medication Delivery Devices Medications and Antidotes Decontamination Issues Psychological Issues Physiologic Concerns Children are more vulnerable to agents that produce vomiting or diarrhea. Because of their larger body surface area they are more susceptible to hypothermia after having been decontaminated. Since Children’s lungs are generally not fully matured until 8 years of age, exposure to a chemical agent at an early age may cause developmental problems. 5 Physiologic Concerns Many chemical warfare agents are carcinogenic and mutagenic and may pose long term problems for children who are exposed in an attack. Because children’s bones are more flexible there are fewer fractures that can be used as trauma markers, therefore, internal injuries may be over looked. Developmental Concerns Young children do not have the cognitive ability to determine when or how to escape from danger. Young children, toddlers and infants do not have the motor skills to escape from the site of a WMD Incident. Nerve agents are known to cause neurophychiatric effects, what is unknown is how long these effects will last in children. 6 Psychological Issues Children are at risk for post traumatic stress disorder after experiencing a WMD event. In a WMD Event they may witness the deaths of their siblings, peers or even their parents. Even children not directly involved in the event may be affected by the repeated showings of the event by the media. “The CNN Effect” Nerve agents are known to have degenerative cognitive effects on patients, but it is unknown how permanent these effects will be in the pediatric population. Personal Protective Equipment Most gas masks and protective equipment are designed for use by adults and are not suitable for use by children. 7 Personal Protective Equipment Continued Attempts have been made over the years to develop protective masks for children. This is an example of a gas mask designed by Walt Disney in the early 1940’s for use by children. Examples of Pediatric Protective Equipment 8 Examples of Pediatric Protective Equipment Continued Personal Protective Equipment Continued Although numerous attempts have been made to develop safe and effective pediatric protective equipment, no truly successful devices have been produced as yet. In Israel during the first Gulf War 8 people, including 6 children, died due to improper use of protective masks. 9 Nerve Agent Issues Children can be disproportionately affected by exposure to chemical agents. Generally, because they are inhaled, the can poise a greater threat to children due to their more rapid respiratory rates. Lethal dose of SARIN Nerve Agent Antidote Kits The current NAAK is the: Antidote Treatment Nerve Agent, Auto-Injector (ATNAA) (Replaces the Mark 1 Kit) The ATNAA consists of one Auto injector that delivers Atropine 2 mg in 0.7 ml Pralidoxime Chloride 600 mg in 2 ml Convulsant Antidote for Nerve Agents (CANA). Diazepam 10 mg in 2 ml 10 Autoinjector Effectiveness Continued Rapid absorption of the antidote following automatic injection is enhanced by the degree of tissue dispersion achieved by the autoinjector. Autoinjector medications are more efficiently diffused into surrounding muscle tissue due to the force with which it is expelled from the injector. Pediatric Auto Injectors 1.0 mg Dose 2.0 mg Dose 0.5 mg Dose 11 Walter Reed Pediatric Nerve Agent Treatment Guide Symptoms Triage Level Atropine Pralidoxime Diazepam Asymptomatic Delayed None None None Miosis, Mild Delayed None None None Rhinnorhea Miosis Immediate: 0.05 mg/kg IV 25-50 mg/kg For any Neurologic effect 30 days to 5 years Repeat as needed Repeat q 1 hr and any other Moderate 0.05 to 0.3 mg/kg IV q 5-10 min until Watch for: symptom Admit To a max 5 mg/dose respiratory status Muscle Rigidity improves 5 years and older Laryngospasm 0.05 to 0.3 mg/kg IV Tachycardia To a max 10 mg/dose Apnea, Immediate: 0.05-0.1 mg/kg 25-50 mg/kg May repeat q 15-30 min Convulsions, Severe No Maximum IV or IM as Above Cardiac Arrest Admit ICU Repeat q 5-10 min As above Source: Walter Reed Army Medical Center Atropine Continued If only standard MARK 1 kits are available, a 2.0 mg atropine autoinjector may be used. Note that infants and small children are at risk of being injured by the autoinjector needle. The most significant adverse side effect of high dose atropine in the younger patient is the inhibition of sweating. Source: USAMRICD 12 The “Nord-Ost” Incident In October 2002, Chechen separatists seized a Moscow theater, taking over 800 hostages. Russian special forces assaulted the theater using a gas based on Fentanyl in an attempt to “Knock-Out” everyone in the theater. At least 120 hostages died from the effects of the gas, 14 were children. Although hard information remains difficult to obtain, it appears that the pediatric hostages died at over twice the rate of the adult hostages. The “Nord-Ost” Incident Continued 13 Biological Agent Issues Children can be disproportionately affected by exposure to biological agents. Children are more vulnerable to agents that produce vomiting or diarrhea. Because children breathe at a faster rate than adults they would be subject to relatively larger doses of an agent during the same period of exposure as an adult. Anthrax Anthrax is a bacterial disease caused by B anthracis and considered a potent biological weapon of mass destruction. Attempts to weaponize B anthracis were made as early as 1916, by Germany. They were attempting to contaminate raindeer herds in Norway and disrupt the movement of supplies from the allies to Russia. 14 Anthrax Continued The anthrax vaccine currently available in the US is not recommended for children by its manufacturer because it was only tested on age groups between 18 and 65 years. No pediatric study of its effectiveness has apparently ever been done. Some authorities have stated that the risk of vaccinating children with the current preparation would have to be weighed against the risk of not using every possible defense to protect children who have actually, or potentially been exposed to anthrax. Antibiotics Pediatric Dosing for Anthrax Exposure The drugs of choice for prophylaxis are Ciprofloxin, penicillin or amoxicillin. (20 to 40 mg/kg/day div TID to QID) NOTE - A genetically engineered BW agent might be resistant to penicillin or amoxicillin. The strain of anthrax used in the 2001 Bio-Terror Letter Attacks was sensitive to penicillin. In penicillin resistant cases, the drug of choice is doxycycline. (2 to 4 mg/kg/day div BID) The discoloration of teeth often associated with doxycycline is typically not seen until after taking six courses of the antibiotic. Source: USAMRIID 15 Anthrax Continued Doxycycline is normally not used in pediatric treatment because of side effects. However, in this situation it is possible that benefits will outweigh the possible disadvantages, and one course of doxycycline is not likely to cause staining of the teeth. Smallpox It first appeared in China and the Far East at least 2000 years ago. Used by the British during the French Indian War and later against the American Colonists during their attack on Quebec. There is some evidence that it may have been used by the Confederates against the Union forces during the American Civil War.
Recommended publications
  • PERFORM SELF-AID for MILD NERVE AGENT POISONING (For Use of This Form, See AMEDDC&S HRCOE Pam 350-10, the Proponent Is MCCS-OPE)
    AMEDDC&S HRCOE PAM 350-10 EFMB Test Score Sheet WARRIOR SKILLS — PERFORM SELF-AID FOR MILD NERVE AGENT POISONING (For use of this form, see AMEDDC&S HRCOE Pam 350-10, the proponent is MCCS-OPE) CANDIDATE’S RANK AND NAME CANDIDATE # TASK: PERFORM SELF-AID FOR MILD NERVE AGENT POISONING. CONDITIONS: You are wearing your protective mask and MOPP gear (or remaining MOPP gear is available) and have been exposed to a nerve agent. One set of MARK I nerve agent antidote auto injectors or one Antidote Treatment, Nerve Agent, Auto- injectors (ATNAA) is available. STANDARDS: Correctly identify six of eight signs and symptoms of mild nerve agent poisoning, administer the antidote to self in the proper sequence, and secure the auto-injector within 5 minutes. NOTE: THIS TASK HAS BEEN MODIFIED FOR EFMB TESTING PURPOSES ONLY. PERFORMANCE STEPS/MEASURES GO NO-GO NOTES: 1. The ATNAA system is a nerve agent antidote device that will be used by the Armed Forces. A single ATNAA delivers both atropine and pralidoxime chloride (2 PAM Cl). The ATNAA will replace the MARK I when supplies are exhausted. 2. Nerve agent antidote training aids will be used to train and evaluate this task. Actual auto-injectors will not be used. 1. Identify mild signs and symptoms of nerve agent poisoning by stating six of the eight to the evaluator. EVALUATOR STATES: “NAME SIX OF THE EIGHT SIGNS AND SYMPTOMS OF MILD NERVE AGENT POISONING.” EVALUATOR WILL INITIAL NEXT TO EACH ONE THAT IS STATED BY THE CANDIDATE. NOTE: Time begins after the evaluator states the above statement to the candidate.
    [Show full text]
  • Nerve Agent Information for Emergency Medical Services And
    August 2018 NERVE AGENT INFORMATION FOR EMERGENCY MEDICAL SERVICES AND HOSPITALS **Meticulous attention to standard protocols for personal protection, recognizing toxidromes, and treating patients continues to be the best way to prepare for and respond to chemical agent exposures** PURPOSE This document provides a quick refresher on standard protocols for recognizing, treating, and protecting yourself from nerve agent exposures. Comprehensive follow-up guidance for Law Enforcement, Fire, EMS, HazMat, and Hospital-Based First Receivers incorporating lessons learned and best practices from the recent United Kingdom incidents will be forthcoming. BACKGROUND Nerve agents are extremely toxic chemical warfare agents. Several nerve agents exist and are generally categorized as either “high volatility” or “low volatility” chemicals, a measure of how likely they are to disperse in air. A high volatility nerve agent (easily dispersed in air) means that the exposure is likely to occur from breathing in its vapors resulting in the rapid onset of symptoms. A low volatility nerve agent (not easily dispersed in air) typically gets absorbed through the skin and has a delayed onset of signs and symptoms. An example of a high volatility nerve agent is sarin, whereas VX is a low volatility agent. In the body, a nerve agent exerts its effects by inhibiting an enzyme (acetylcholinesterase), resulting in acute illness – specifically, cholinergic crisis. Organophosphorus or carbamate pesticides produce similar effects to nerve agents. SIGNS AND SYMPTOMS OF
    [Show full text]
  • FM 4-02.285. Multiservice Tactics, Techniques, and Procedures For
    ARMY, MARINE CORPS, NAVY, AIR FORCE MULTISERVICE TACTICS, TECHNIQUES, AND PROCEDURES FOR TREATMENT OF CHEMICAL AGENT CASUALTIES AND CONVENTIONAL MILITARY CHEMICAL INJURIES FM 4-02.285 (FM 8-285) MCRP 4-11.1A NTRP 4-02.22 AFTTP (I) 3-2.69 SEPTEMBER 2007 DISTRIBUTION RESTRICTION: Approved for public release; distribution is unlimited. MULTISERVICE TACTICS, TECHNIQUES, AND PROCEDURES FOREWORD This publication has been prepared under our direction for use by our respective commands and other commands as appropriate. RUSSELL J. CZERW JAMES F. AMOS Major General, DC Lieutenant General, US Marine Corps Commander, US Army Medical Deputy Commandant for Combat Department Center and School Development and Integration T. L. DAVISON THOMAS J. LOFTUS Captain, US Navy Major General, USAF, MC, CFS Acting Assistant Surgeon General Navy Warfare Development Command Health Care Operations Office of the Surgeon General This publication is available through the US Army at Army Knowledge Online (AKO) (www.us.army.mil) and at the General Dennis J. Reimer Training and Doctrine Digital Library (www.train.army.mil) websites; through the US Marine Corps website (https://www.doctrine.usmc.mil); through the US Navy at Navy Knowledge Online (https://www.nko.navy.mil) accessed via the Navy Warfare Library (located on the Reference Page) and the Navy Warfare Development Command SIPRNET Doctrine Discussion Group (DDG) (www.nwdc.navy.smil.mil); and through the US Air Force at the Air Force Publishing website (www.e-publishing.af.mil). PREFACE 1. Purpose This publication provides multiservice tactics, techniques, and procedures (MTTP) and is designed for use as a reference for trained members of the Armed Forces Medical Services and other medically qualified personnel on the recognition and treatment of chemical agent casualties and conventional military chemical injuries.
    [Show full text]
  • ATP 4-02.85. Multi-Service Tactics
    *ATP 4-02.85 MCRP 3-40A.1 *NTRP 4-02.22 *AFTTP(I) 3-2.69 MULTI-SERVICE TACTICS, TECHNIQUES, AND PROCEDURES FOR TREATMENT OF CHEMICAL WARFARE AGENT CASUALTIES AND CONVENTIONAL MILITARY CHEMICAL INJURIES AUGUST 2016 DISTRIBUTION RESTRICTION: Approved for public release; distribution is unlimited. *This publication supersedes ATP 4-02.85/NTRP 4-02.22/AFTTP(I) 3-2.69, dated 19 August 2015. FOREWORD This publication has been prepared under our direction for use by our respective commands and other commands as appropriate. This publication is available at the Army Publishing Directorate site at https://armypubs.army.mil/ and at the Central Army Registry site at https://atiam.train.army.mil/catalog/dashboard. Also available through the United States Marine Corps Doctrine site at https://www.doctrine.usmc.mil/, United States Navy site at https://ndls.nwdc.navy.mil/, and through the United States Air Force Doctrine site at https://doctrine.af.mil/. ATP 4-02.85, C1 MCRP 4-11.1A NTRP 4-02.22 AFTTP(I) 3-2.69 Change 1 Army Techniques Publication No. 4-02.85 Headquarters Marine Corps Reference Publication 4-11.1A Department of the Army Navy Technical Reference Publication 4-02.22 Washington, DC, 16 April 2019 Air Force Tactics, Techniques, and Procedures (Instruction) 3-2.69 Multi-Service Tactics, Techniques, and Procedures for Treatment of Chemical Warfare Agent Casualties and Conventional Military Chemical Injuries 1. This change updates pyridostigmine bromide (PB) use in accordance with Food and Drug Administration (FDA)-approved labeling and updates the Marine Corps number to ATP 4-02.85/MCRP 3-40A.1/NTRP 4-02.22/AFTTP(I) 3-2.69, Multi-Service Tactics, Techniques, and Procedures for Treatment of Chemical Warfare Agent Casualties and Conventional Military Chemical Injuries.
    [Show full text]
  • Iowa CHEMPACK Program
    CHEMPACK Overview Federal Program – Centers for Disease Control and Prevention (CDC) – Division of Strategic National Stockpile (DSNS) Initiated post September 2001 to address large scale chemical releases – Forward placement of chemical antidotes – Primarily organophosphates 1 CHEMPACK Program Mission Implement a nationwide project for the “forward” placement of nerve agent antidotes. To provide state and local governments a sustainable resource that increases their capability to respond quickly to a nerve agent event 2 Overview Designed to utilized as secondary response assets – Delivery to response area within 60 minutes – Does not absolve local initial response responsibilities – Can not be utilized to supplant local initial cache SNS assets would be utilized as tertiary response to large scale event 3 Illinois CHEMPACK Locations 4 Iowa CHEMPACK Locations 5 CHEMPACK Container: 60.5 (L) X 32.5 (W) X 60.5 (H) Approximate weight 550 lbs Container serial DEA approved number wire mesh Lockable latches Container content list Swivel casters EMS Style CHEMPACK Containers Assets – Federal ownership maintained – Shelf Life Extension Program (SLEP) Pharmaceutical supplies only – 85% self administration – 15% multi-use vials Designed to treat 454 patients – 30% mild exposure – 40% moderate exposure 7 – 30% severe exposure Pharmaceuticals – forward placement of Nerve Agents (Antidote Treatment Nerve Agent Autoinjector) ATNAA Auto-Injector Antidote Kits – 2.1mg atropine / 0.7 ml and 600mg / 2ml Pralidoxime Chloride (2-Pam) / 2ml – 1,200
    [Show full text]
  • Medical Aspects of Chemical Warfare
    Medical Chemical Defense Acquisition Programs Chapter 20 MEDICAL CHEMICAL DEFENSE ACQUISITION PROGRAMS † KEITH VESELY, DVM, PHD,* AND JONATHAN NEWMARK, MD INTRODUCTION MEDICAL CHEMICAL ACQUISITION ORGANIZATIONS MEDICAL CHEMICAL ACQUISITION PROCESSES AND CONCERNS Concept Development Technology Development System Development and Demonstration Production and Development Operations and Support Phase Acquisition Manufacturing Strategy Acquisition Test and Evaluation Strategy Acquisition Business and Contracting Strategy Specific Concerns in Medical Chemical Defense STATUS OF ACQUISITION PROGRAMS OF RECORD Lifecycle Management Products Sustainment Programs Products in Advanced Development SUMMARY *Colonel, US Army; Joint Product Manager, Medical Identification and Treatment Systems, Chemical Biological Medical Systems Joint Project Manage- ment Office, 64 Thomas Johnson Drive, Frederick, Maryland 21702 †Colonel, US Army; Deputy Joint Program Executive Officer, Medical Systems, Joint Program Executive Office for Chemical/Biological Defense, Skyline #2, Suite 1609, 5203 Leesburg Pike, Falls Church, Virginia 22041; Adjunct Professor, Department of Neurology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 645 Medical Aspects of Chemical Warfare INTRODUCTION The Department of Defense (DoD) requires medical proval (DoD policy stipulates that military personnel countermeasures to treat or mitigate illness resulting will only receive medical products approved by the from exposure to chemical,
    [Show full text]
  • Essential Medicines, Medical Countermeasures, and Critical Inputs for the List Described in Section 3(C) of the Executive Order 13944
    Drug and Biologic Essential Medicines, Medical Countermeasures, and Critical Inputs for the List Described in Section 3(c) of the Executive Order 13944 *List of drugs for critical care does not include the following: diagnostic agents and medical gases other than isoflurane for general anesthesia + Additional critical inputs have been identified by FDA but have not yet been expressly identified on this list because of the need to consider how to share this additional critical input information in a manner that is consistent with applicable disclosure law while providing our federal partners with the information they need to implement their obligations under the EO IN MCM USE DRUG NAME* DOSAGE FORMS CRITICAL INPUTS ONLY Drug Category: Gastrointestinal Agents Famotidine oral / IV API only (blank cell) Lactulose liquid API only (blank cell) Loperamide oral API only (blank cell) Pantoprazole IV API only (blank cell) Drug Category: Anticonvulsants Phenytoin IV API only (blank cell) Levetiracetam oral / IV API only (blank cell) Drug Category: Antiemetics Ondansetron IV API only (blank cell) Drug Category: Anticoagulants / Antiplatelet Alteplase IV API only (blank cell) Apixaban oral API only (blank cell) Aspirin oral API only (blank cell) Ticagrelor oral API only (blank cell) Enoxaparin SQ API, heparin, crude heparin (blank cell) Heparin IV API and crude heparin (blank cell) Protamine IV API, source proteins (blank cell) Vitamin K IV API only (blank cell) Andexanet alfa injection IV genetically modified variant of human FXa (blank cell) Argatroban
    [Show full text]
  • Scientific Advisory Board
    OPCW Scientific Advisory Board Twenty-Second Session SAB-22/WP.2/Rev.1 8 – 12 June 2015 10 June 2015 ENGLISH only RESPONSE TO THE DIRECTOR-GENERAL'S REQUEST TO THE SCIENTIFIC ADVISORY BOARD TO PROVIDE FURTHER ADVICE ON ASSISTANCE AND PROTECTION EXECUTIVE SUMMARY 1. This note contains the SAB's Response to the Director-General's Request to the Scientific Advisory Board to Provide Further Advice on Asistance and Protection (Paragraph 9.20 of SAB-21/1, dated 27 June 2014). 2. This report was drafted as a follow up to the Director-General's previous request for advice from the SAB. Readers are advised to refer to the previous report (SAB-21/WP.7, dated 29 April 2014) when considering the information presented herein. 3. This report contains recommendations addressed to the Technical Secretariat of the OPCW. It is made available to the public for informational purposes, but is not meant to be used by the public. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient. The information contained in this publication is accurate to the best of the OPCW's knowledge; however, neither the OPCW nor the independent experts of the Scientific Advisiory Board assume liability under any circumstances for the correctness or comprehensiveness of such informaion or for the consequences of its use. Annex: Response to the Director-General’s Request to the Scientifc Advisory Board to Provide Further Advice on Assistance and Protection CS-2015-9252(E) distributed 12/06/2015 *CS-2015-9252.E* SAB-22/WP.2/Rev.1 Annex page 2 Annex RESPONSE TO THE DIRECTOR-GENERAL’S REQUEST TO THE SCIENTIFC ADVISORY BOARD TO PROVIDE FURTHER ADVICE ON ASSISTANCE AND PROTECTION 1.
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use Pyridostigmine Bromide Tablets USP 30 Mg Safely and Effectively
    PYRIDOSTIGMINE BROMIDE- pyridostigmine bromide tablet Surgeon General-Department of the Army (TSG-DA) ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Pyridostigmine Bromide Tablets USP 30 mg safely and effectively. See full prescribing information for Pyridostigmine Bromide Tablets USP 30 mg. Pyridostigmine Bromide USP Tablets 30 mg for Oral Use Initial U.S. Approval: 1955 CAUTION: USE PYRIDOSTIGMINE BROMIDE AS PRETREATMENT ONLY. AFTER EXPOSURE TO SOMAN, USE ATROPINE AND 2-PAM. ALWAYS USE PROTECTIVE GARMENT(S) See full prescribing information for complete boxed warning. Pyridostigmine bromide is for use as a pretreatment for exposure to soman nerve agent. Pyridostigmine bromide alone will not protect against exposure to soman. The efficacy of pyridostigmine bromide is dependent upon the rapid use of atropine and pralidoxime (2-PAM) after soman exposure. Primary protection against exposure to chemical nerve agents is the wearing of protective garments. Pyridostigmine bromide must not be taken after exposure to soman. If taken immediately before soman exposure (e.g., when the gas attack alarm is given) or at the same time as poisoning by soman, it is not expected to be effective and may exacerbate the effects of a sub-lethal exposure to soman. INDICATIONS AND USAGE Pyridostigmine bromide is a reversible cholinesterase inhibitor indicated for pretreatment against the lethal effects of soman nerve agent poisoning. (1) Pyridostigmine bromide is for use in conjunction with Protective garments, including a gas mask, and Immediate atropine and pralidoxime therapy at the first sign of nerve agent poisoning. (1) DOSAGE AND ADMINISTRATION One 30 mg tablet every 8 hours.
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use ATNAA Safely and Effectively
    ATNAA ATROPINE AND PRALIDOXIME CHLORIDE AUTO-INJECTOR- atropine and pralidoxime chloride Meridian Medical Technologies, Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ATNAA safely and effectively. See full prescribing information for ATNAA. ATNAA (atropine and pralidoxime chloride injection), for intramuscular use Initial U.S. Approval: 2002 INDICATIONS AND USAGE ATNAA, a combination of atropine, a cholinergic muscarinic antagonist, and pralidoxime chloride, a cholinesterase reactivator, is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity in adults. (1) DOSAGE AND ADMINISTRATION ATNAA is intended as an initial treatment as soon as symptoms appear; definitive medical care should be sought immediately. (2.1) Dosage for Mild Symptoms: If a service member experiences some or all of the mild symptoms, they should self- administer one injection intramuscularly into the lateral thigh muscle or buttocks. If, at any time after the first dose, the service member develops any of the severe symptoms or if the mild symptoms are not relieved, a buddy should administer two additional injections intramuscularly in rapid succession. (2.2) Dosage for Severe Symptoms: If a service member has any of the severe symptoms, immediately buddy-administer three injections intramuscularly into the service member's lateral thigh muscle or buttocks in rapid succession. (2.2) DOSAGE FORMS AND STRENGTHS Injection: Each single-dose ATNAA autoinjector contains atropine (2.1 mg/0.7 mL) plus pralidoxime chloride (600 mg/2 mL). (3) CONTRAINDICATIONS None. (4) WARNINGS AND PRECAUTIONS Cardiovascular (CV) Risks: Tachycardia, palpitations, premature ventricular contractions, flutter, fibrillation, etc.
    [Show full text]
  • PYRIDOSTIGMINE BROMIDE Tablets, USP 30 Mg Rx Only
    Pyridostigmine Bromide Package Insert page 1 PYRIDOSTIGMINE BROMIDE Tablets, USP 30 mg Rx only CAUTION! PYRIDOSTIGMINE BROMIDE IS FOR USE AS A PRETREATMENT FOR EXPOSURE TO THE CHEMICAL NERVE AGENT SOMAN. PYRIDOSTIGMINE ALONE WILL NOT PROTECT AGAINST EXPOSURE TO SOMAN. THE EFFICACY OF PYRIDOSTIGMINE IS DEPENDENT UPON THE RAPID USE OF ATROPINE AND PRALIDOXIME (2-PAM) AFTER SOMAN EXPOSURE. PRIMARY PROTECTION AGAINST EXPOSURE TO CHEMICAL NERVE AGENTS IS THE WEARING OF PROTECTIVE GARMENTS INCLUDING MASKS, HOODS AND OVERGARMENTS DESIGNED SPECIFICALLY FOR THIS USE. INDIVIDUALS MUST NOT RELY SOLELY UPON PRETREATMENT WITH PYRIDOSTIGMINE AND THE ANTIDOTES ATROPINE AND PRALIDOXIME (2-PAM) TO PROVIDE COMPLETE PROTECTION FROM POISONING BY THE CHEMICAL NERVE AGENT SOMAN. PYRIDOSTIGMINE MUST NOT BE TAKEN AFTER EXPOSURE TO SOMAN. IF PYRIDOSTIGMINE IS TAKEN IMMEDIATELY BEFORE EXPOSURE (E.G., WHEN THE GAS ATTACK ALARM IS GIVEN) OR AT THE SAME TIME AS POISONING BY SOMAN, IT IS NOT EXPECTED TO BE EFFECTIVE, AND MAY EXACERBATE THE EFFECTS OF A SUB-LETHAL EXPOSURE TO SOMAN. FOR MILITARY COMBAT MEDICAL USE ONLY DESCRIPTION Pyridostigmine bromide tablets, USP 30 mg. Pyridostigmine bromide is an orally active cholinesterase inhibitor. Its chemical name is: 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate. Pyridostigmine Bromide Package Insert page 2 CAS registration number is 101-26-8. White tablet each imprinted with letters “PBT”. Pyridostigmine bromide has a molecular formula of C9H13BrN202, a molecular weight of 261.12, and the following molecular structure: The inactive ingredients included in the tablet formula are: colloidal silicon dioxide, lactose anhydrous, and stearic acid or, alternatively; lactose, starch, silica precipitated, talc, and magnesium stearate.
    [Show full text]
  • Nerve Agent Information for Emergency Medical Services And
    August 2018 NERVE AGENT INFORMATION FOR EMERGENCY MEDICAL SERVICES AND HOSPITALS **Meticulous attention to standard protocols for personal protection, recognizing toxidromes, and treating patients continues to be the best way to prepare for and respond to chemical agent exposures** PURPOSE This document provides a quick refresher on standard protocols for recognizing, treating, and protecting yourself from nerve agent exposures. Comprehensive follow-up guidance for Law Enforcement, Fire, EMS, HazMat, and Hospital-Based First Receivers incorporating lessons learned and best practices from the recent United Kingdom incidents will be forthcoming. BACKGROUND Nerve agents are extremely toxic chemical warfare agents. Several nerve agents exist and are generally categorized as either “high volatility” or “low volatility” chemicals, a measure of how likely they are to disperse in air. A high volatility nerve agent (easily dispersed in air) means that the exposure is likely to occur from breathing in its vapors resulting in the rapid onset of symptoms. A low volatility nerve agent (not easily dispersed in air) typically gets absorbed through the skin and has a delayed onset of signs and symptoms. An example of a high volatility nerve agent is sarin, whereas VX is a low volatility agent. In the body, a nerve agent exerts its effects by inhibiting an enzyme (acetylcholinesterase), resulting in acute illness – specifically, cholinergic crisis. Organophosphorus or carbamate pesticides produce similar effects to nerve agents. SIGNS AND SYMPTOMS OF
    [Show full text]